• Vanessa Acquaah (chair)

• Emma Salib (co-chair)

• Elsie Horne (subject matter expert)

• Victor Lhoste (subject matter expert)

• Kaeden Bunting (lay), Hayley Hall (lay)

• Trishna Bharadia (patient)

• Thomas Smith (patient)

• Shira Peleg Hasson (clinical)

No conflicts declared by panel

Approved

• The project's benefits were clearly articulated, demonstrating advantages for both the public and patient groups E.g This analysis may highlight a research gap, paving the way for new treatment options. 

• The application was well thought out and it was clear why further research into prostate cancer is important.

• The lay summary was written well for a lay audience and gave a clear explanation of the different types of prostate cancer.

• The request provided a good overview of the ways Pfizer may engage with patients and communities affected by cancer and demonstrated Pfizer’s commitment to working with a range of communities.

• The panel raised several comments on other aspects of the application, including:
  
  

  • More details on the presentation of analytic outputs

  • More detail on how Pfizer’s patient dissemination channels will specifically address health inequalities